Neutralizing Antibody Conversion With OnabotulinumtoxinA From Global Studies Across Multiple Indications With A Focus On Movement Disorders: A Meta-Analysis
Objective: A meta-analysis of clinical trial data across 10 indications for onabotulinumtoxinA was performed to assess incidence of neutralizing antibody (nAb) formation with a focus…Botulinum toxin injections for sialorrhea in Parkinson´s disease and parkinsonism: 5 years follow up
Objective: Investigate the safety and efficacy of botulinum toxin type A in Parkinson´s disease and parkinsonism patients affected by sialorrhea Background: Sialorrhea is excessive salivation…Experiences of home-based dance participation in people with Parkinson’s
Objective: To investigate experiences of people with PD in using digital resources for home-based dance participation during the COVID-19 pandemic. Background: Dance is associated with…Data Driven Paths to Advancing Precision Medicine Strategies for Parkinson’s Disease: Critical Path for Parkinson’s Consortium
Objective: An update on the accomplishments of the Critical Path for Parkinson’s (CPP) Consortium. Background: The pharmaceutical pipeline for Parkinson’s disease (PD) is rapidly expanding. Data sharing will facilitate decision making during the development…Primary Palliative Care for Huntington Disease
Objective: To develop a pilot program integrating primary palliative care with interdisciplinary care for Huntington disease (HD). Goals: 1) train HD team members to facilitate…The effect of Tuina in Traditional Chinese Medicine in treatment of Parkinson’s disease (Non-motor symptoms): a pilot clinical study
Objective: To evaluate the efficacy and safety of Tuina treatment in treating non-motor symptoms (NMS) of Parkinson’s disease (PD) and provide preliminary data for conducting…Adopting a low-cost multidisciplinary telemedicine approach for falls prevention in Parkinson´s Disease.
Objective: Healthcare services have been compromised during the COVID-19 pandemic, owing to limited access to multidisciplinary care. Our main aims are to describe the methods…Measuring progression of Parkinson’s disease cardinal signs in the Phase 2 SPARK study
Objective: To evaluate a novel quantitative measure of Parkinson’s disease (PD) severity and progression in a Phase II clinical trial. Background: Cinpanemab, a monoclonal antibody,…Defining LRRK2-PD subsets based on olfactory function in the PPMI
Objective: A major goal of the Parkinson Progression Marker Initiative (PPMI) is to identify clinical and biomarker defined disease subsets that may demonstrate differing disease…Celiac disease-related antibodies in Parkinson’s Disease patients: a case control study.
Objective: To compare anti-transglutaminase and antigliadin antibodies between Parkinson’s disease patients and healthy controls. A detailed gastrointestinal symptom investigation was studied and compared between patient…
- « Previous Page
- 1
- …
- 9
- 10
- 11
- 12
- 13
- …
- 132
- Next Page »